These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

175 related articles for article (PubMed ID: 25139313)

  • 41. Combination long-acting β-agonists and inhaled corticosteroids compared with long-acting β-agonists alone in older adults with chronic obstructive pulmonary disease.
    Gershon AS; Campitelli MA; Croxford R; Stanbrook MB; To T; Upshur R; Stephenson AL; Stukel TA
    JAMA; 2014 Sep; 312(11):1114-21. PubMed ID: 25226477
    [TBL] [Abstract][Full Text] [Related]  

  • 42. β2-agonist therapy in lung disease.
    Cazzola M; Page CP; Rogliani P; Matera MG
    Am J Respir Crit Care Med; 2013 Apr; 187(7):690-6. PubMed ID: 23348973
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Advances in drug delivery: Is triple therapy the future for the treatment of chronic obstructive pulmonary disease?
    Salama RO; Young PM; Rogueda P; Lallement A; Iliev I; Traini D
    Expert Opin Pharmacother; 2011 Aug; 12(12):1913-32. PubMed ID: 21714776
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Ultra long-acting beta 2-agonists in development for asthma and chronic obstructive pulmonary disease.
    Cazzola M; Matera MG; Lötvall J
    Expert Opin Investig Drugs; 2005 Jul; 14(7):775-83. PubMed ID: 16022567
    [TBL] [Abstract][Full Text] [Related]  

  • 45. A randomised, placebo-controlled, Phase II, dose-ranging trial of once-daily treatment with olodaterol, a novel long-acting β2-agonist, for 4 weeks in patients with chronic obstructive pulmonary disease.
    Maleki-Yazdi MR; Beck E; Hamilton AL; Korducki L; Koker P; Fogarty C
    Respir Med; 2015 May; 109(5):596-605. PubMed ID: 25829298
    [TBL] [Abstract][Full Text] [Related]  

  • 46. The effect of indacaterol during an acute exacerbation of COPD.
    Segreti A; Fiori E; Calzetta L; Sabatini M; Segreti V; Rogliani P; Cazzola M
    Pulm Pharmacol Ther; 2013 Dec; 26(6):630-4. PubMed ID: 23578980
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Bedoradrine for treating asthma and chronic obstructive pulmonary disease.
    Antoniu S
    Expert Opin Investig Drugs; 2014 Aug; 23(8):1149-56. PubMed ID: 24938936
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Umeclidinium/vilanterol combination inhaler efficacy and potential impact on current chronic obstructive pulmonary disease management guidelines.
    Davidson JF; Donohue JF; Ohar JA
    Expert Opin Drug Saf; 2015 Feb; 14(2):317-24. PubMed ID: 25598422
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Additive efficacy of short-acting bronchodilators on dynamic hyperinflation and exercise tolerance in stable COPD patients treated with long-acting bronchodilators.
    Kitaguchi Y; Fujimoto K; Komatsu Y; Hanaoka M; Honda T; Kubo K
    Respir Med; 2013 Mar; 107(3):394-400. PubMed ID: 23245993
    [TBL] [Abstract][Full Text] [Related]  

  • 50. The combination of umeclidinium bromide and vilanterol in the management of chronic obstructive pulmonary disease: current evidence and future prospects.
    Feldman GJ; Edin A
    Ther Adv Respir Dis; 2013 Dec; 7(6):311-9. PubMed ID: 24004659
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Effects of long-acting bronchodilators in COPD patients according to COPD severity and ICS use.
    Decramer M; Dahl R; Kornmann O; Korn S; Lawrence D; McBryan D
    Respir Med; 2013 Feb; 107(2):223-32. PubMed ID: 23219347
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Efficacy and tolerability of indacaterol 75 μg once daily in patients aged ≥40 years with chronic obstructive pulmonary disease: results from 2 double-blind, placebo-controlled 12-week studies.
    Kerwin EM; Gotfried MH; Lawrence D; Lassen C; Kramer B
    Clin Ther; 2011 Dec; 33(12):1974-84. PubMed ID: 22177371
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Safety and efficacy of dual bronchodilation with QVA149 in COPD patients: the ENLIGHTEN study.
    Dahl R; Chapman KR; Rudolf M; Mehta R; Kho P; Alagappan VK; Chen H; Banerji D
    Respir Med; 2013 Oct; 107(10):1558-67. PubMed ID: 23867808
    [TBL] [Abstract][Full Text] [Related]  

  • 54. β(2) -adrenoceptor agonists: current and future direction.
    Cazzola M; Calzetta L; Matera MG
    Br J Pharmacol; 2011 May; 163(1):4-17. PubMed ID: 21232045
    [TBL] [Abstract][Full Text] [Related]  

  • 55. [New bronchodilators and combinations in COPD treatment].
    Günay S; Sarıaydın M; Yılmaz Demirci N
    Tuberk Toraks; 2016 Sep; 64(3):240-245. PubMed ID: 28366158
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Ultra Long-Acting β-Agonists in Chronic Obstructive Pulmonary Disease.
    Burkes RM; Panos RJ
    J Exp Pharmacol; 2020; 12():589-602. PubMed ID: 33364854
    [TBL] [Abstract][Full Text] [Related]  

  • 57. β
    Billington CK; Penn RB; Hall IP
    Handb Exp Pharmacol; 2017; 237():23-40. PubMed ID: 27878470
    [TBL] [Abstract][Full Text] [Related]  

  • 58. [Recent advances in study of long β(2)-adrenoceptor agonist].
    Ge XY; Mo YM; Pan L; Cheng MS
    Yao Xue Xue Bao; 2016 Dec; 51(12):1838-44. PubMed ID: 29908535
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Indacaterol in chronic obstructive pulmonary disease: an update for clinicians.
    Yorgancioglu A
    Ther Adv Chronic Dis; 2012 Jan; 3(1):25-36. PubMed ID: 23251766
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Asthma and COPD: A Focus on β-Agonists - Past, Present and Future.
    Baker JG; Shaw DE
    Handb Exp Pharmacol; 2024; 285():369-451. PubMed ID: 37709918
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.